Text Size

fMRI of Vulnerable Brain Regions in Persons at Risk for Alzheimer's Disease (ALZ)

This study is enrolling participants by invitation only.
Sponsor:
Collaborators:
National Institutes of Health (NIH)
National Institute on Aging (NIA)
Information provided by:
University of Wisconsin, Madison
ClinicalTrials.gov Identifier:
NCT00478491
First received: May 22, 2007
Last updated: September 27, 2010
Last verified: September 2010
History of Changes
  Purpose

The purpose of this study is to investigate the organization of memory and develop future methods for early detection of AD. Using functional magnetic resonance imaging (fMRI), we examine the responsiveness of the brain to memory tasks, specifically focusing on regions of the brain (the mesial temporal lobe and posterior cingulate) that are known to be involved in early stages of Alzheimer's disease (AD). Of interest are differences in brain activation between people with and without a family history of AD and other risk factors.


Condition
Magnetic Resonance Imaging
Alzheimer's Disease
Dementia
Adult Children
Risk

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: fMRI of Vulnerable Brain Regions in Persons at Risk for Alzheimer's Disease

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University of Wisconsin, Madison:

Biospecimen Retention:   Samples Without DNA

plasma and serum


Estimated Enrollment: 390
Study Start Date: January 2003
Estimated Study Completion Date: July 2010
Groups/Cohorts
1
Persons with a parent with Alzheimer's disease
2
Persons whose parents survived to old age without memory problems
3
Persons with diagnosed mild cognitive impairment
4
Persons without memory problems

  Eligibility

Ages Eligible for Study:   40 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Persons with a parent with Alzheimer's disease will be recruited from the Wisconsin Registry for Alzheimer's Prevention (WRAP). Persons with MCI will be recruited from the UW clinics and satellite clinics. Controls for the above study groups will be recruited from the WRAP and the local community.

Criteria

Inclusion Criteria:

  • MCI Group: Diagnosis of mild cognitive impairment
  • AD Family History Group: Confirmed family history of Alzheimer's and concurrent enrollment in the Wisconsin Registry for Alzheimer's Prevention (WRAP)
  • Control Groups: Cognitively healthy and both parents survived past age 70 with no memory problems

Exclusion Criteria:

  • Claustrophobia
  • Metallic or electronic implants or devices that are not MRI-safe
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00478491

Locations
United States, Wisconsin
University of Wisconsin - Wisconsin Comprehensive Memory Program
Madison, Wisconsin, United States, 53792
Sponsors and Collaborators
University of Wisconsin, Madison
National Institutes of Health (NIH)
National Institute on Aging (NIA)
Investigators
Principal Investigator: Sterling C Johnson, PhD University of Wisconsin/VA GRECC
  More Information

Additional Information:
Website for the Sterling Johnson Imaging Lab  This link exits the ClinicalTrials.gov site
Website for the Wisconsin Comprehensive Memory Program  This link exits the ClinicalTrials.gov site

Publications:

Responsible Party: Sterling Johnson, PhD, University of Wisconsin - Madison
ClinicalTrials.gov Identifier: NCT00478491     History of Changes
Other Study ID Numbers: 2002-515, NIH RO1 AG021155A
Study First Received: May 22, 2007
Last Updated: September 27, 2010
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
 Tauopathies
Neurodegenerative Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders

ClinicalTrials.gov processed this record on May 23, 2013